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Subtractive hybridization cloning: An efficient technique to detect
overexpressed mRNAs in diabetic nephropathy
Technical Note
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Hyperfiltration, associated with kidney hypertrophy and hyper-
plasia, are early markers of diabetic nephropathy [1, 2]. Proce-
dures for the identification of renal molecules potentially involved
in this early process are of particular interest. In order to detect
hyperexpression of major renal proteins in early diabetic nephrop-
athy, we used the well-known model of streptozotocin (STZ)-
induced diabetes in rats [3] and a robust technique of subtracted
hybridization between normal and diabetic kidneys [4–6]. Two
subtracted probes were elaborated after hydridization of diabetic
rat kidney cDNA with control rat kidney mRNA. These probes
were used to screen a diabetic rat kidney cDNA library. Two
clones were overexpressed in diabetic rat kidneys and corre-
sponded to the multi-drug resistance 1 (mdr 1) cDNA and to the
b-amyloid protein precursor (bPP), respectively. This study de-
scribes the results of subtractive hybridization cloning in rats, as
well as some data obtained in human kidney sections originating
from diabetic patients.
METHODS
Experimental model
Sixty Sprague-Dawley rats received a single injection of STZ
(60 mg/kg) in citrate buffer, as previously described [7]. Twenty
rats received only citrate buffer. After two to six days, the
STZ-treated group had overt diabetes. They were treated with
insulin 0.2 to 0.4 U/kg/day in order to maintain glycemia under 11
mmol/liter and glycosuria under 5 mmol/24 hr. Every 15 days,
urinary output, glycemia, glycosuria, proteinuria and creatinine
clearance were measured. The animals in both groups were
sacrified after 15, 30, 60 and 99 days. The mean 6 SD creatinine
clearances were 3.6 6 0.6 ml/min at day 15, 3.6 6 0.7 ml/min at
day 30, 3.2 6 0.6 ml/min at day 60 and 2.6 6 0.6 ml/min at day 99.
In the control group, creatinine clearance was 2.4 6 0.4 ml/min at
day 30 and 2.8 6 0.4 ml/min at day 99. Mean proteinuria in the
diabetic group increased modestly from 7 6 2 mg/24 hr at day 1 to
37 6 13 mg/24 hr at day 99.
Construction of the diabetic rat kidney cDNA library and the
subtracted probes
Five micrograms of Poly A1 RNA from diabetic rat kidney
cortex were prepared at day 99 using the Fast Track kit (British
Biotechnology). The library was made with the commercial cDNA
library kit (Pharmacia) after subcloning of the cDNAs in lambda
gt10. The library was titrated and contained 2 3 106 independent
clones.
Two independent subtracted probes were prepared as previ-
ously described [4–6]. The method is presented in Figure 1.
Briefly, after 99 days of diabetes, rats were killed and Poly A1
RNA was extracted (Fast Track kit, British Biotechnology). Then,
2.5 mg (first probe) and 3 mg (second probe) of polyA1 RNA
were reverse transcripted using 32P-a-dCTP (Amersham) and the
cDNA synthesis kit (Boehringer Mannheim Corp.). These cDNAs
were hybridized 24 hours with an excess (50 to 60 mg) of Poly A1
RNA purified from normal rat kidney; the calculated R0t [initial
concentration of nucleic acid (moles of nucleotides/liter) 3 time
(seconds)] was 1000 with a 20-fold mass excess of Poly A1 RNA
from normal rat kidney. The hybridization buffer was: NaSCN 5
M, Tris 1 M and phenol equilibrated in 0.1 M Tris, pH 8.0, as
described by Travis and Sutcliffe [8]. The hybridization reaction
was performed overnight at room temperature. After chloroform
extraction and ethanol precipitation, the pellet was resuspended
in 1 ml NaPO4 buffer 50 mM at pH 6.9. The total radioactivity was
measured and the sample was eluted at different phosphate
buffers (50 mM, 140 mM and 400 mM PO4) on hydroxyapatite
60°C-preheated resin columns (BioRad). The single strand cDNA
(corresponding to the subtractive probe) was eluted at 140 mM
phosphate buffer (Fig. 1). Two subtractive probes were indepen-
dently obtained and corresponded respectively to 4.5 and 5.8% of
the total initial radioactive count. These probes were labeled us-
ing 32P-a-dCTP and the Random Primer kit (Amersham). The
diabetic rat kidney cDNA library was screened simultaneously
with these two probes (106 clones were sceened). Only clones that
were positive with the two probes were further purified using the
PEG technique [6]. Sequencing was performed either directly
from the phage using a lambda gt10 primer (Promega sequencing
kit) or after subcloning of the inserts in Bluescript plasmid
(Stratagene) using the sequenase commercial kit (Amersham).
The obtained sequence was searched in Genbank database and
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the deduced amino acid sequence was compared to the amino
acid sequences of the NBRF-PIR database.
RNA extraction and Northern blot analysis
Total RNA extraction from cortex rat kidney and agarose gel
(0.9%) electrophoresis of total RNA (10 mg) in the presence of
20% formaldehyde followed by Northern blot transfer were
performed as previously described [6] using the Gene Screen Plus
membrane (New England Nuclear). The different purified inserts
were labeled with 32P-a-dCTP by the random primer technique
(Amersham). Hybridization conditions and processing of filters
were performed as previously described, and autoradiographs
were quantitated with a video-densitometer (Applige`ne) [9]. The
same filter was boiled for five minutes in 2 3 SSC 1 0.1% SDS
and rehybridized with a radiolabeled b-actin cDNA probe.
Western blot
Kidney cortex from control or diabetic rats was lysed at day 99
using a sucrose buffer containing EDTA, PMSF, benzamidin,
aprotinin and Triton X-100. Twenty-five micrograms of proteins
were run on a 7.5% denaturing polyacrylamide gel and blotted on
a nitrocellulose filter (PVDF, DuPont) using a semi-dry transfer
system (Trans Blot SD Semi Dry Transfer Cell; Biorad). The filter
was blocked at 37°C for two hours in PBS 1 0.1% Tween 20
(Sigma)1 2% bovine serum albumin (Sigma). In order to detect
P-glycoprotein (P-gp), the product of the mdr 1 gene, the filter
was probed two hours at 37°C with 1.5 mg/ml of the anti-P-gp
MRK 16 monoclonal antibody (Valbiotech). P-gp protein was
then detected after successive incubations with (1) a polyclonal
goat anti-mouse antibody conjugated to alkaline phosphatase, and
(2) the nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phos-
phate complex. In order to detect bPP protein, the filter was
Fig. 1. Schema of the method used to prepare
the subtractive probe.
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probed with 1 mg/ml monoclonal anti-bPP antibody (monoclonal
antibody Alz 90, generated to a synthetic peptide corresponding
to amino acid residues 511 to 608 of bPP and known to recognize
human, monkey and rat bPP; Boehringer) for two hours at 37°C
on a rolling stirrer. The revelation was done using chemolumines-
cence (ECL kit, Amersham).
Immunocytochemical studies of bPP and of the mature Ab
protein
Immunocytochemical studies were performed on frozen, 4%
paraformaldehyde-fixed rat kidney tissue from either control or
diabetic rats that were sacrified on day 99. Amyloid precursor
protein was detected using a monoclonal anti-human Alzheimer
precursor protein (clone 22C11; Boehringer Mannheim). The
working concentration was 3 mg/ml in PBS-BSA 3%, in the
presence of 10% final concentration normal rabbit serum. The
fixed antibodies were detected by (1) 64 mg/ml of a rabbit
anti-mouse antibody (Dako); (2) the APAAP mouse monoclonal
complex (Dako), and (3) the Fast-red TR/naphtol AS-MX tablet
set in Tris buffer pH 8.0. Sections were then counterstained with
hematoxylin.
Immunocytochemical studies were also performed on human
kidney biopsies obtained in our nephrologic unit between 1975
and 1994, from 30 adult patients (28 percutaneous kidney biopsies
and 2 post-mortem biopsies) with a variety of kidney diseases:
diabetic nephropathy (13 patients, six with type I diabetes and 7
with type II diabetes), focal sclerosis (4 patients), IgA nephropa-
thy (4 patients), thrombotic microangiopathy (2 patients), acute
tubular necrosis (2 patients), chronic interstitial nephritis (1
patient), membranous glomerulonephritis (4 patients) and one
normal kidney section. The bPP and Ab proteins were detected
on human kidney paraffin-embedded sections using either the
anti-bPP monoclonal antibody (clone 22C11; Boehringer Mann-
heim) at a 3 mg/ml final concentration, or the anti-human Ab
monoclonal antibody (Dako), 2 mg/ml final concentration. The
fixed antibodies were detected by successive incubations with: (1)
3 mg/ml biotinylated anti-mouse antibody (Vector Laboratories);
(2) streptavidin-horseradish peroxydase complex 1/500 (Amer-
sham); and (3) 3 to 39-Diaminobenzidin (Sigma), 0.05% final
concentration in phosphate buffer pH 7.6 with 0.015% final
concentration H2O2. Sections were then counterstained with
hematoxylin. In control experiments, the primary antibody was
omitted. As a positive control for Ab labeling, we used a brain
section from a patient with Alzheimer’s disease (gift from Dr. J.J.
Hauw).
RESULTS
Differential screening and isolation of the cDNA clones
The diabetic rat kidney cDNA library (106 clones) was screened
with the two independent subtracted probes. After the first
screening, more than 50 clones were positive. After successive
purification of phage plaques, only six clones were found to be
positive with both probes. Overexpression in diabetic rat kidneys
as compared to control kidneys was defined by at least a fivefold
increase in mRNA expression assessed by Northern blot. Among
the six purified clones, three were overexpressed. Two clones were
sequenced at the present time. The first clone was a 1.5 kb insert
that was sequenced and was found to be identical to the mdr 1
gene (homology score in the NBRF-PIR database: 100%). The
mdr 1 gene encodes for P-glycoprotein (P-gp), a 170 kDa plasma
membrane protein that is an energy-dependant drug efflux pump
involved in the resistance of tumor cells to many hydrophobic
cytotoxic drugs [10, 11].
The second clone corresponded to a 2.8 kb insert. Partial
sequencing (373 nucleotides) was performed directly from the
phage. The sequence corresponded to the so-called RNAG in
Genebank database (Ref. X007648); RNAG is the rat bPP, highly
homologous to human bPP, which is the precursor of the small
peptide Ab that accumulates and forms plaques in the brain of
patients with Alzheimer’s disease [12, 13]. The amino acid homol-
ogy score was 96.3% with rat bPP and 94.4% with mouse protease
nexin II, which is the N terminus part of bPP [14].
Semiquantitative analysis using Northern blot and Western
blot
Northern blot analysis with mdr 1 cDNA (Fig. 2) demonstrated
an increase in mdr 1 expression in diabetic rat kidneys, as
compared to normal rat kidneys. This hyperexpression was
present at day 15, and further increased at day 99 (;6-fold
increase). The mdr 1 gene product, P-gp, was weakly detectable in
control kidneys and more abundant in diabetic kidneys (Fig. 3).
Northern blot analysis using the bPP insert as a probe showed an
increase in bPP mRNA in diabetic kidney as compared to control
rat kidney (Fig. 4). This increase was present after 15 days of
diabetes and was even more important after 99 days (;8-fold
increase). Using the anti-human bPP monoclonal antibody Alz 90
as a probe, immunoblotting analysis showed a major band with an
apparent molecular mass of 90 kDa. The protein was markedly
increased in all the diabetic kidneys tested (Fig. 5).
Immunocytochemical localization of bPP and of the mature Ab
protein
Immunocytochemical localization of bPP on rat kidney speci-
mens is shown in Figure 6. In normal rat kidney, bPP was
moderately present in tubular sections and hardly detectable in
Fig. 2. Northern blot analysis. Twenty micrograms of total RNA from
control (lane 1) and diabetic rat cortex kidneys after 15 days (lane 2) and
99 days (lane 3) of diabetic course. The blot was probed with 32P-a-labeled
mdr 1 clone (upper panel) and alpha-actin probe (lower panel). Arrows
correspond to 28 S and 18 S RNA.
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glomeruli. In diabetic rat kidney sections, bPP appeared to be
markedly increased, both in tubular sections and in the glomeruli,
in which epithelial and mesangial cells appeared to be stained.
Immunocytochemical studies were also performed on human
kidney sections. We screened 13 biopsies from diabetic patients,
17 biopsies from patients suffering various types of glomerular,
vascular or tubuloinerstitial diseases, and one normal kidney
section. Results of bPP expression were similar to those obtained
in rats, with an increased expression of bPP in all the tested
specimens from diabetic patients (not shown), as compared to the
non-diabetic cases and to the normal kidney specimen. Interest-
ingly, in five out of the eight biopsies showing marked diabetic
glomerulosclerosis, we detected the presence of mature Ab
deposition. As shown in Figure 7, mature Ab deposition appears
as fine granular deposits that were mostly located in the peritu-
bular and perivascular interstitial region of the cortex. Congo red
staining of the sections was negative (not shown). Ab deposition
was only present in type I diabetic patients with advanced
nephropathy. All the control biopsies were found to be negative.
As a positive control, we used a brain section from a patient who
died from Alzheimer’s disease.
DISCUSSION
Using subtractive hybridization cloning, we found an overex-
pression of mdr 1 and bPP mRNAs in streptozotocin-induced
diabetic rat kidneys. The overexpressions of both mdr 1 and bPP
are attested by Northern blot and Western blot experiments. For
bPP, the increased expression is further documented by immuno-
cytochemical studies on rat and human diabetic kidney sections.
Our data demonstrate the utility of using subtractive probes to
detect differentially expressed mRNAs in the same tissue in two
different clinical situations. We used a protocol based on cDNA:
mRNA hybridization and recovery of unhybridized cDNA by
chromatography through hydroxyapatite [4–6]. This technique is
rarely used today, because of the difficulty in getting a sufficient
amount of mRNA in order to drive the subtractive hybridization
to completion; it is replaced by PCR-based protocols of the
subtraction cDNA library [15, 16] and by the technique of
differential display of mRNAs by RT-PCR [17]. Polymerase chain
reaction (PCR)-based methods have the advantages of easier
feasibility and rapidity. Furthermore, they lead to purification of
cDNAs that correspond to very rare, highly differentially ex-
pressed mRNAs. With our protocol, we probably missed the rare
differentially expressed clones, but we did find clones correspond-
ing to abundant mRNAs (as shown on Northern blots from
normal tissue), which are overexpressed in diabetic kidneys and
can be easily studied on human tissue.
The first clone that was found to be overexpressed in diabetic
Fig. 3. Western blot analysis. Twenty-five micrograms of control (lane 1)
and diabetic (lane 2) cortex rat kidney proteins were prepared at day 99,
and run on a 7.5 polyacrylamide gel. The blot was probed with the MRK
16 monoclonal antibody and revealed using the alkaline phosphatase
system. Arrows correspond to 132 kDa and 84 kDa.
Fig. 4. Northern blot analysis. Twenty micrograms of total RNA from
control (lane 1) and diabetic rat cortex kidneys after 15 days (lane 2) and
99 days (lane 3) of diabetic course. The blot was probed with 32P-a-labeled
bPP clone (upper panel) and a-actin probe (lower panel). Arrows
correspond to 28 S and 18 S RNA.
Fig. 5. Western blot analysis. Twenty-five micrograms of control (lane 1)
and diabetic (lane 2) cortex rat kidney proteins were prepared at day 99,
and run on a 7.5 polyacrylamide gel. The blot was probed with the Alz 90
monoclonal antibody and revealed using the chemoluminescence system.
Arrows correspond to 84 kDa and 47 kDa.
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rat kidneys corresponds to the mdr 1 gene. The overexpression of
mdr 1 in streptozotocin-induced diabetic rat kidney has not been
previously described. We cannot rule out a role for streptozotocin
exposure as a mechanism of induction. However, this hypothesis
appears very unlikely since streptozotocin is not known to be
transported by the mdr 1 gene product [18]. Furthermore, the
increased expression is persistent at day 99. In cultured human
renal cells, mdr 1 mRNA is increased by acidification and
hyperosmolality [19]. Such mechanisms could explain the renal
overexpression of mdr 1 in our diabetic rats.
The second overexpressed mRNA is bPP mRNA. We docu-
mented bPP overexpression by Northern blot, Western blot and
immunocytochemistry. bPP belongs to a family of membrane-
associated proteins present in brain, non-neural tissues and
cultured cells [12]. The non-neural isoform contains a domain
homologous to the Kunitz family of serine protease inhibitor
(KPI) [20]. The secreted amino-terminal fragment containing the
KPI domain is identical to the previously described serine pro-
tease inhibitor, protease nexin II [14]. This domain is present in
our sequence. It has been documented that bPP mRNA was
widely distributed and present in kidneys [12, 13], but modulation
of renal bPP expression in diseases has not been described.
Despite numerous studies, the precise role of bPP is still un-
known. In early diabetic nephropathy, bPP could play a role in
extracellular matrix remodeling, as documented for protease
nexin I [21]. bPP could also act as an autocrine growth promoting
molecule, as described in vitro in fibroblasts [22].
The precursor bPP can be processed by several alternative
pathways, some of them leading to the direct secretion of the
4-kDa peptide Ab, which accumulates in senile plaques and blood
vessels in Alzheimer’s disease [23, 24]. In the present study, Ab
deposition was detected in five human renal biopsies from pa-
tients with long-term type I diabetes. No patient was known to
have Alzheimer’s disease. Interestingly, recent data point to a role
Fig. 7. Ab detection in human kidneys and brain sections using the
monoclonal anti-human Ab antibody and the biotin-streptavidin-peroxy-
dase revelation system. (A) Brain section from a patient who died of
Alzheimer’s disease (3250). (B) Kidney section from a patient with renal
failure due to IgA nephropathy (3250). (C) Kidney section from a patient
after 56 years of insulin-dependant diabetic course (3500). (D) Kidney
section a patient after 17 years of insulin-dependant diabetic course; the
arrows correspond to the fine Ab deposits (3250). Reproduction of this
figure in color was made possible by a grant from Produits Roche (Neuille
sur Seine, France).
Fig. 6. B-amyloid protein precursor (bPP) detection in rat kidney sec-
tions using the monoclonal anti-bPP 22C11 and the APAAP system. (A)
Control kidney section (3500). (B) Diabetic (day 99) rat kidney section
(3500). Reproduction of this figure in color was made possible by a grant
from Produits Roche (Neuille sur Seine, France).
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for glycation in the pathogenesis of Alzheimer’s disease, suggest-
ing that high glucose can modulate bPP metabolism [25, 26]. It
has been demonstated that advanced glycosylation end products
can accelerate Ab aggregation and promote the formation of
non-soluble aggregates [25]. Non-enzymatic glycation can thus
explain the increased synthesis of bPP and the accumulation of
Ab in diabetic nephropathy.
In conclusion, substrative hybridization is a potent method to
characterize overexpressed mRNAs in diabetic kidneys. Further
studies are needed to determine the precise relevance of these
results in human diabetes and to study the potential roles of mdr
1/P-gp, bPP and Ab in diabetic nephropathy.
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APPENDIX
Abbreviations used in this article are: bPP, b-amyloid protein precur-
sor; KPI, Kunitz family of protease inhibitor; mdr 1, multi-drug resistance
1; P-gp, P-glycoprotein; RT-PCR, reverse transcribed-polymerase chain
reaction; STZ, streptozotocin.
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